Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Salivary Gland Neoplasms 1Prostatic Neoplasms 1Bites and Stings 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 85Specimen Handling 66Prednisone 66Androgen Antagonists 60Abiraterone Acetate 58apalutamide 56Radiosurgery 53darolutamide 48Radiotherapy 47Leuprolide 47abiraterone 46Docetaxel 43Pluvicto 32Radiation 31Biopsy 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Surveys and Questionnaires 29relugolix 28gallium 68 PSMA-11 26Standard of Care 26pembrolizumab 25Goserelin 25Triptorelin Pamoate 24bicalutamide 23Gonadotropin-Releasing Hormone 23Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Androgen Receptor Antagonists × 1 year × Clear all
NCT04946370 2026-04-21

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Weill Medical College of Cornell University

Phase 1/2 Recruiting
52 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡